Welcome to the Porton Newsroom
Porton and Jianxiang Forge Strategic Partnership to Build a New High Ground for Large-scale Peptide Drug Manufacturing
Porton and Jianxiang partner to deliver integrated peptide CDMO services from development to commercial manufacturing, offering scalable, compliant solutions for global clients.
Porton Wins “2025 Best CRO” Award from Daewoong Pharma
Daewoong Pharma highly recognized Porton’s contributions to its drug development through active cooperation based on Porton’s excellent capabilities and expertise.
Porton Newsletter - February 2026 Recap
Porton Newsletter - February 2026 Recap
Porton Newsletter - January 2026 Recap
Porton Newsletter - January 2026 Recap
Porton Newsletter - Q4 2025 Recap
Technical Enabling
Services & Solutions
Company Events
ESG
Marketing Activities
Others
A Porton Publication in ACS Journal on Polymorphic Crystallization Kinetics Study and Control
Porton's new study in ACS journal explores methodology for designing processes to isolate pure metastable API polymorphs using crystallization kinetics.
Porton Achieves EU QP Certification for Chongqing Manufacturing Facility
Porton Pharma's Chongqing facility successfully completes EU QP Audit. Third site to meet European quality standards for drug manufacturing.
Porton&Nona: Strategic Partnership for Complex Antibody Therapy
Global biotech Nona partners with CDMO Porton to accelerate complex antibody drug development and commercialization.
Porton Newsletter - November 2025 Recap
Technical Enabling
Services & Solutions
Company Events
ESG
Marketing Activities
Others
